CompletedPhase 2NCT04963231

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Studying Genetic obesity

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Rhythm Pharmaceuticals, Inc.
Principal Investigator
David Meeker, MD
Rhythm Pharmaceuticals, Inc.
Intervention
Setmelanotide(drug)
Enrollment
164 target
Eligibility
6-65 years · All sexes
Timeline
20212024

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04963231 on ClinicalTrials.gov

Other trials for Genetic obesity

Additional recruiting or active studies for the same condition.

See all trials for Genetic obesity

← Back to all trials